Methods for the treatment of cancer
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsGeorge F. Vande Woude, Nicholas Schulz, Renping Zhou, Ira Daar, Marianne Oskarsson
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising an effective cancerous cell growth inhibiting amount of paclitaxel, or a paclitaxel derivative, and an effective cancerous cell growth inhibiting amount of an active agent which inhibits cancerous cell growth by exerting an effect on mammalian cell cycle during G.sub.1 or S-phase of the cell division cycle to inhibit said cancerous cell growth and methods of using same.
Claims40
A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent, wherein said paclitaxel and DNA cross-linking anti-neoplastic agent act synergistically to inhibit cancerous cell growth in said human.
A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent, wherein said paclitaxel exerts an effect on a human cell division cycle during M phase to inhibit cancerous growth, said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth, and said paclitaxel and DNA cross-linking anti-neoplastic agent act synergistically to inhibit cancerous cell growth in said human.
A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent,
- wherein said paclitaxel and DNA cross-linking anti-neoplastic agent are administered within eight hours of each other and
- act synergistically to inhibit cancerous cell growth in said human.
A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent,
- wherein said placlitaxel exerts an effect on a human cell division cycle during M phase to inhibit cancerous growth,
- said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth,
- said paclitaxel and DNA cross-linking anti-neoplastic agent are administered within eight hours of each other, and
- said paclitaxel and DNA cross-linking anti-neoplastic agent act synergistically to inhibit cancerous cell growth in said human.
A method of treating cancer by administering to a human paclitaxel and DNA cross-linking anti-neoplastic agent,
- wherein said paclitaxel and DNA cross-linking anti-neoplastic agent are administered within one hour of each other and
- act synergistically to inhibit cancerous cell growth in said human.
A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent,
- wherein said placlitaxel exerts an effect on a human cell division cycle during M phase to inhibit cancerous growth, said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth,
- said paclitaxel and DNA cross-linking anti-neoplastic agent are administered within one hour of each other, and
- said paclitaxel and DNA cross-linking anti-neoplastic agent act synergistically to inhibit cancerous cell growth in said human.
A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent,
- wherein said paclitaxel and DNA cross-linking anti-neoplastic agent are administered to said human in such temporal proximity to each other so as to simultaneously achieve levels of said paclitaxel and DNA cross-linking anti-neoplastic agent in said human sufficient to act synergistically to inhibit cancerous cell growth in said human.
A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent in such temporal proximity to each other so as to simultaneously achieve levels of said paclitaxel and DNA cross-linking anti-neoplastic agent in said human sufficient to act synergistically to inhibit cancerous cell growth in said human,
- wherein said paclitaxel exerts an effect on a human cell division cycle during M phase to inhibit cancerous growth, and
- said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.
Dependencies are inferred from the claim text.